How Canada's Updates to Clinical Trial Processes Are Shaping New Regulatory Standards by Yewande Oduwole

For sponsors running clinical trials in Canada, regulatory affairs has long been measured by a familiar set of expectations and milestones: a clean clinical trial application, a Notice of No Objection (NNO), amendments and notifications filed on time, and inspection records that hold up under review. That work remains essential. However, Health Canada’s ongoing modernization of the clinical trials framework signals a broader shift, one that changes not just how submissions are prepared, but what the regulatory function is expected to deliver across the life of a trial.

The proposed regulatory framework builds on principles the industry has discussed for years: risk proportionality, quality by design, and lifecycle oversight. That shift is unfolding alongside Health Canada’s full adoption of ICH E6(R3), which went into effect as of April, 2026, and has already made many of these principles more explicit in expectations for trial design, conduct, oversight, and data governance.

What is changing is how explicitly these principles are moving from aspiration to expectation. Understanding that shift, and preparing for it early, will separate sponsors who simply meet the new requirements from those who use them to strengthen how their programs are run.

What is Actually Changing?

Canada's clinical trial modernization is not a single future event. It is a series of concrete shifts, some already in effect and others on a defined timeline.

ICH E6(R3) is now the operating standard

On April 1, 2026, Health Canada fully adopted ICH E6(R3), the updated international guideline for good clinical practice. This is not a future aspiration. It is already shaping how sponsors are expected to approach quality management, risk-based monitoring, critical-to-quality factors, sponsor and service-provider responsibilities, and data governance across their trials.

Consultation is complete, and Health Canada has responded

The proposed clinical trials regulations were open for public comment from the end of 2025 through April 2026, generating 214 unique responses and four engagement sessions attended by approximately 500 participants. In September 2026, Health Canada published its “What We Heard” report, grouping feedback into three themes: regulatory changes (including concerns about review timelines, contingent authorization, and terms and conditions), requests for guidance clarification, and ideas for future reform.

Health Canada has indicated it will consider the regulatory concerns raised and provide further clarification on implementation details.

An interim policy is already in effect

On the same September date in 2026, Health Canada implemented an interim policy advancing three modernization measures while the broader regulations are finalized:

• Streamlined REB notification for multi-site trials: sponsors may use a single research ethics board of record with notification to Health Canada, rather than securing separate approvals at each site.
• More flexible qualified investigator requirements: expanding the range of appropriately qualified professionals who may serve as qualified investigators, while maintaining requirements for training and oversight.
• Documented informed consent, including remote and electronic approaches: providing a practical framework for decentralized and remote trial activities while maintaining informed consent requirements.

The proposed regulatory framework introduces structural changes. The draft guidance (GUI-0100) and supporting regulatory text introduce several changes to how trials are authorized and overseen in Canada:

• Contingent authorization replaces the current No Objection Letter model, with a defined pathway from application through a 30-day review period. Stakeholders have raised questions about the operational implications of this concept, and Health Canada may provide further clarification before implementation.
• Risk-proportionate requirements allow sponsors to tailor their approach to monitoring, adverse event collection, and quality management based on what matters most to participant safety and data integrity, rather than applying a uniform standard regardless of trial complexity.
• Terms and conditions can be imposed or amended throughout the lifecycle of a trial. Consultation feedback supported this authority in principle, but called for narrower criteria, a more defined process, and predictable timelines for how it would be applied.
• Sponsor accountability for service providers is written directly into the proposed regulations. Delegating trial activities to a CRO or other service provider does not diminish the sponsor's obligation to oversee the quality and integrity of that work.
• Lifecycle oversight tools, including a direction-to-cease authority for Phase IV trials and post-trial safety reporting obligations, extend regulatory expectations well beyond database lock.

The timeline is concrete. Final regulations are expected to be published in Spring 2027, followed by a one-year coming-into-force period. The modernized clinical trials regulations are anticipated to take effect in spring 2028. These changes mean that the regulatory environment for clinical trials in Canada is already different from what it was eighteen months ago and will look different again by 2028.

From a Finish Line to an Ongoing Relationship

The contingent authorization pathway and lifecycle terms and conditions described above represent more than procedural updates. They reflect a shift in the relationship between the sponsor and the regulator. Under the traditional model, authorization could function as something of a finish line—a sponsor assembled the package, secured the authorization, and moved into clinical conduct. Under the proposed framework, authorization increasingly marks the start of an ongoing regulatory relationship rather than the end of a process.

This new framework changes the central question. It is no longer only whether a submission is acceptable at the point of review, but whether the sponsor’s entire oversight model is robust enough to hold up through the course of the trial. These are different questions, and they call for different capabilities.

Why Judgment Becomes the Differentiating Skill

Much of the language in the modernized framework and ICH E6 (R3) is deliberately principles-based. Terms such as “proportionate to the risk,” “critical-to-quality factors,” and “fit-for-purpose” do not prescribe a fixed set of actions. They describe what to consider, and they leave the application of that thinking to the teams closest to the trial.

This is where regulatory affairs move beyond administration and into strategy. Interpreting an ambiguous requirement, weighing risk against expectations, and translating that judgment into a decision a sponsor, investigator and contract research organization (CRO) can act on is the core focus of strategic regulatory affairs. It is the difference between a program that anticipates where its commitments will become pressure points early in the process and one that identifies them late, when they are more costly to address.

What This Means for Sponsors

For organizations planning or conducting trials in Canada, several implications stand out.
Oversight of service providers is receiving greater regulatory emphasis. Delegating a task to a CRO or vendor moves the work, but it does not change accountability. The sponsor remains answerable for the quality of the oversight, which means the governance model warrants the same rigor applied to the science. And the guidance also places clearer expectations on sponsors to assess and oversee service providers, while Canada’s proposed framework would introduce more direct regulatory oversight of third parties conducting trial activities.

Risk-based thinking must be built-in early. A framework organized around critical-to-quality factors rewards teams that identify what genuinely matters to participant safety and data integrity at the design stage, rather than retrofitting that logic after a protocol is finalized.

Regulatory input belongs upstream. The value of regulatory expertise is highest when it shapes decisions while they remain open, not when it is asked to manage the consequences of decisions already made.

Preparing Before the Framework Is Final

With ICH E6(R3) already adopted, interim flexibilities in effect, and final regulations anticipated in Spring 2027 with a Spring 2028 coming-into-force date, the interval before the full framework takes effect is an opportunity to prepare rather than wait. Practical steps include conducting a gap assessment of current standard operating procedures against the proposed risk-based model, clarifying who owns interpretation and oversight decisions across functions, and positioning regulatory expertise to inform study design and vendor governance from the outset.

Sponsors who approach this purely as a compliance exercise may meet the requirements. Sponsors who treat it as an opportunity to strengthen how regulatory decisions are made may be better positioned to move with greater speed and confidence, by building the judgment the framework now expects into how they operate.

In Conclusion: A Partnership Model, Not Just a Process Update

Canada's modernized clinical trial framework is doing more than revising a set of rules. It is raising the bar for what sponsors are expected to demonstrate—not just at the point of submission, but across the full course of a trial. Oversight accountability, risk-based design, and principled regulatory judgment are no longer differentiators. They are the baseline. Sponsors who recognize that shift early, and build the capabilities to meet it, will be better positioned to move their programs forward without costly course corrections.

This is the approach we take at Altasciences. Our regulatory affairs experts work alongside sponsors to build that strategic foundation, integrating regulatory strategy with nonclinical, clinical, and manufacturing activities so that programs are designed to anticipate regulatory expectations rather than react to them. In an environment where oversight, accountability, and lifecycle judgment increasingly define regulatory success, that early alignment is what allows sponsors to move forward with confidence.

To learn how Altasciences can support your regulatory strategy across Health Canada, FDA, and global regulatory pathways, get in touch with one of our experts.

About the Author

Yewande (Wande) Oduwole, RAC, is a regulatory affairs professional with 10 years of combined experience

;across quality assurance, regulatory consulting, drug development, and clinical research, complemented by four years of prior pharmacy practice.

She has led regulatory submissions and strategy and supported health authority interactions for pharmaceutical and biotechnology development programs.

Her experience includes practical regulatory interpretation, submission planning and authoring, and cross-functional team management. She also brings broader experience in global health access initiatives and project management, as well as IVD and drug regulatory systems strengthening, affording her a multidisciplinary perspective on regulatory frameworks across different regions.

_{This blog was first published in November 2026.}
 

FAQ: Clinical Trials in Canada

What are the advantages of conducting early-phase clinical trials in Canada?

Canada offers a streamlined CTA pathway, experienced clinical research infrastructure, access to diverse study populations, and alignment with international standards, including ICH guidelines. Data generated in Canadian clinical trials can also support regulatory submissions in other jurisdictions, including the United States.

What is a Clinical Trial Application (CTA) in Canada?

A Clinical Trial Application (CTA) is submitted to Health Canada to obtain authorization to conduct a Phase I–III clinical trial involving a drug in Canada. Regulatory affairs teams can support CTA strategy, preparation and submission, responses to Health Canada, and ongoing amendments and notifications throughout clinical development.

How does regulatory affairs support a clinical trial beyond the initial submission?

Regulatory affairs extends beyond preparing a CTA or IND. Regulatory teams can help sponsors assess development risks, prepare for health authority interactions, maintain applications, manage amendments and notifications, and align regulatory strategy with clinical, nonclinical, manufacturing, and CRO activities throughout drug development.

How long does Health Canada take to review a Clinical Trial Application?

Health Canada’s standard review period for a CTA is 30 calendar days. Certain eligible comparative bioavailability and bioequivalence studies may qualify for a seven-day review. This regulatory pathway can make Canada an attractive location for early-phase clinical trials and help sponsors generate clinical data earlier in drug development.